Skip to content
  1. Latest News

Penn Medicine News: Precision Medicine: Access to Real-time Genetic Testing Data Impacts Prescriber Behavior following Minimally Invasive Stent Procedure

“Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic. Following percutaneous coronary intervention (PCI)—a minimally invasive procedure for the treatment of narrowing arteries inside the heart—patients are often prescribed aspirin and antiplatelet medications, which keep stents open by preventing blood platelets from sticking together. However, existing research suggests that some patients—specifically those who carry a mutation of the CYP2C19 gene, which impact the liver’s ability to process the antiplatelet drug, clopidogrel—may not benefit from this drug, but instead would require different antiplatelet medications, such as prasugrel or ticagrelor, to prevent heart attack and stroke.” Read more at Penn Medicine News.

Research Areas